Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of Neratinib, Pertuzumab, and Trastuzumab With Taxol (3HT) in Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC

Next Previous
X
Search
Trial Profile

A Phase 1b Study of Neratinib, Pertuzumab, and Trastuzumab With Taxol (3HT) in Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Neratinib (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel; Pertuzumab; Trastuzumab
  • Indications Advanced breast cancer; Carcinoma; HER2 negative breast cancer; HER2 positive breast cancer; Inflammatory breast cancer; Male breast cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 31 Mar 2022 Status changed from recruiting to active, no longer recruiting.
    • 04 Dec 2018 Planned End Date changed from 1 Jan 2027 to 1 Jan 2026.
    • 29 Jan 2018 Planned End Date changed from 1 Apr 2027 to 1 Jan 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top